Abstract:BackgroundRobust approaches to quantify tumor heterogeneity are needed to provide early decision support for precise individualized therapy. PurposeTo conduct a technical exploration of longitudinal changes in tumor heterogeneity patterns on dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI), diffusion-weighted imaging (DWI) and FDG positron emission tomography / computed tomography (PET/CT), and their association to radiation therapy (RT) response in cervical cancer. Study TypeProspective observational study with longitudinal MRI and PET/CT pre-RT, early-RT (2 weeks), and mid-RT (5 weeks). PopulationTwenty-one FIGO IB2-IVA cervical cancer patients receiving definitive external beam RT and brachytherapy. Field Strength/Sequence1.5T, precontrast axial T-1-weighted, axial and sagittal T-2-weighted, sagittal DWI (multi-b values), sagittal DCE MRI (<10 sec temporal resolution), postcontrast axial T-1-weighted. AssessmentResponse assessment 1 month after completion of treatment by a board-certified radiation oncologist from manually delineated tumor volume changes. Statistical TestsIntensity histogram (IH) quantiles (DCE SI10% and DWI ADC(10%), FDG-PET SUVmax) and distribution moments (mean, variance, skewness, kurtosis) were extracted. Differences in IH features between timepoints and modalities were evaluated by Skillings-Mack tests with Holm's correction. Area under receiver-operating characteristic curve (AUC) and Mann-Whitney testing was performed to discriminate treatment response using IH features. ResultsTumor IH means and quantiles varied significantly during RT (SUVmean: 28-47%, SUVmax: 30-59%, SImean: 8-30%, SI10%: 8-19%, ADC(mean): 16%, P < 0.02 for each). Among IH heterogeneity features, FDG-PET SUVCoV (16-30%, P=0.011) and DW-MRI ADC(skewness) decreased (P=0.001). FDG-PET SUVCoV was higher than DCE-MRI SICoV and DW-MRI ADC(CoV) at baseline (P < 0.001) and 2 weeks (P=0.010). FDG-PET SUVkurtosis was lower than DCE-MRI SIkurtosis and DW-MRI ADC(kurtosis) at baseline (P=0.001). Some IH features appeared to associate with favorable tumor response, including large early RT changes in DW-MRI ADC(skewness) (AUC=0.86). Data ConclusionPreliminary findings show tumor heterogeneity was variable between patients, modalities, and timepoints. Radiomic assessment of changing tumor heterogeneity has the potential to personalize treatment and power outcome prediction. Level of Evidence: 2 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2018;47:1388-1396.

Addressing Metabolic Heterogeneity in Clear Cell Renal Cell Carcinoma with Quantitative Dixon MRI

Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform

Efficacy of 3D VIBE Dixon Fat Quantification for Differentiating Clear-Cell from Non-Clear-cell Renal Cell Carcinoma.

Quantitative Measurement on Contrast-Enhanced CT Distinguishes Small Clear Cell Renal Cell Carcinoma From Benign Renal Tumors: A Multicenter Study

The Radiogenomic Landscape of Clear Cell Renal Cell Carcinoma: Insights into Lipid Metabolism through Evaluation of ADFP Expression

Radiogenomic associations clear cell renal cell carcinoma: an exploratory study

Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression

Non-Invasive Assessment of Lactate Production and Compartmentalization in Renal Cell Carcinomas Using Hyperpolarized 13C Pyruvate MRI

Quantitative Analysis of Multiphase Contrast-Enhanced CT Images: A Pilot Study of Preoperative Prediction of Fat-Poor Angiomyolipoma and Renal Cell Carcinoma.

Metabolic Reprogramming of Cancer Stem Cells and a Novel Eight-Gene Metabolism-Related Risk Signature in Clear Cell Renal Carcinoma

Dynamic Contrast-enhanced MRI in Renal Tumors: Common Subtype Differentiation Using Pharmacokinetics

Radiomics Correlation to CD68+ Tumor-Associated Macrophages in Clear Cell Renal Cell Carcinoma

Comprehensive Characterization of Metabolism-Associated Subtypes of Renal Cell Carcinoma to Aid Clinical Therapy.

Subtype Differentiation of Small (≤ 4 Cm) Solid Renal Mass Using Volumetric Histogram Analysis of DWI at 3-T MRI

Dynamic Contrast-enhanced MR Imaging in Renal Cell Carcinoma: Reproducibility of Histogram Analysis on Pharmacokinetic Parameters

Metabolic heterogeneity in clear cell renal cell carcinoma revealed by single-cell RNA sequencing and spatial transcriptomics

Serum and Urine Metabolic Fingerprints Characterize Renal Cell Carcinoma for Classification, Early Diagnosis, and Prognosis

Tumor radiomic heterogeneity: Multiparametric functional imaging to characterize variability and predict response following cervical cancer radiation therapy.

Quantitative proteomic analysis reveals sophisticated metabolic alteration and identifies FMNL1 as a prognostic marker in clear cell renal cell carcinoma

Exploring Tumor Heterogeneity: Radiogenomic Assessment of ADFP in Low WHO/ISUP Grade Clear Cell Renal Cell Carcinoma

Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study